skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 3
Patent #:
NONE
Issue Dt:
Application #:
17775040
Filing Dt:
05/06/2022
Publication #:
Pub Dt:
12/08/2022
Inventor:
Dimitrios Karamichos
Title:
Detection and Treatment of Conditions Related to Luteinizing Hormone/Follicle-Stimulating Hormone (LH/FSH) Levels
Assignment: 1
Reel/Frame:
061344/0372Recorded: 10/07/2022Pages: 3
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
11/08/2019
Assignee:
660 PARRINGTON OVAL, ROOM 119
NORMAN, OKLAHOMA 73019
Correspondent:
EDWIN FLORES C/O CHALKER FLORES, LLP
14841 NORTH DALLAS PARKWAY, STE. 545
DALLAS, TX 75254
Assignment: 2
Reel/Frame:
061345/0164Recorded: 10/07/2022Pages: 4
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
08/26/2022
Assignees:
660 PARRINGTON OVAL, ROOM 119
NORMAN, OKLAHOMA 73019
3500 CAMP BOWIE BLVD.
FORT WORTH, TEXAS 76107
Correspondent:
DANIEL CHALKER C/O CHALKER FLORES, LLP
14841 NORTH DALLAS PARKWAY, STE. 545
DALLAS, TX 75254
Assignment: 3
Reel/Frame:
066380/0283Recorded: 01/30/2024Pages: 2
Conveyance:
CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
03/29/2023
Assignee:
NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
6705 ROCKLEDGE DRIVE, SUITE 310, MSC 7980
BETHESDA, MARYLAND 20892-7980
Correspondent:
DIRECTOR, DEITR
NIH, 6705 ROCKLEDGE DRIVE, SUITE 310
MSC 7980
BETHESDA, MD 20892-7980

Search Results as of: 06/19/2024 11:01 AM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT